Development and validation of a new liquid chromatography-tandem mass spectrometry assay for the simultaneous quantification of afatinib, dacomitinib, osimertinib, and the active metabolites of osimertinib in human serum

An LC-MS/MS method for the simultaneous determination of afatinib, alectinib, ceritinib, crizotinib, dacomitinib, erlotinib, gefitinib, and osimertinib in human serum

(2021) Yuji Mukai et al.   THERAPEUTIC DRUG MONITORING

Effects of Pharmacokinetics-related Genetic Polymorphisms on the Side Effect Profile of Afatinib in Patients with Non-Small Cell Lung Cancer

(2019) Hideki Hayashi et al.   LUNG CANCER

Validated LC-MS/MS assay for quantification of the newly approved tyrosine kinase inhibitor, dacomitinib, and application to investigating its metabolic stability

(2019) Ali S. Abdelhameed et al.   PLoS One

Development and validation of a liquid chromatography-tandem mass spectrometry assay for nine oral anticancer drugs in human plasma

(2019) Julie M. Janssen et al.   JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS

FDA- and EMA-Approved Tyrosine Kinase Inhibitors in Advanced EGFR-Mutated Non-Small Cell Lung Cancer: Safety, Tolerability, Plasma Concentration Monitoring, and Management

(2019) Isabelle Solassol et al.   Biomolecules

Bioanalysis of EGFRm inhibitor osimertinib, and its glutathione cycle- and desmethyl metabolites by liquid chromatography-tandem mass spectrometry

(2019) J.J.M. Rood et al.   JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS

High throughput routine determination of 17 tyrosine kinase inhibitors by LC–MS/MS

(2018) Camille Merienne et al.   JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS

Liquid chromatography-tandem mass spectrometric assay for therapeutic drug monitoring of the EGFR inhibitors afatinib, erlotinib and osimertinib, the ALK inhibitor crizotinib and the VEGFR inhibitor nintedanib in human plasma from non-small cell lung cancer patients

(2018) Rafael Reis et al.   JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS

Osimertinib in Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer

(2018) Jean-Charles Soria et al.   NEW ENGLAND JOURNAL OF MEDICINE

Bioanalytical liquid chromatography-tandem mass spectrometric assay for the quantification of the ALK inhibitors alectinib, brigatinib and lorlatinib in plasma and mouse tissue homogenates

(2018) Rolf W. Sparidans et al.   JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS

Risk of Treatment-Related Toxicities from EGFR Tyrosine Kinase Inhibitors: A Meta-analysis of Clinical Trials of Gefitinib, Erlotinib, and Afatinib in Advanced EGFR -Mutated Non–Small Cell Lung Cancer

(2017) Pei Ni Ding et al.   Journal of Thoracic Oncology

Dacomitinib versus gefitinib as first-line treatment for patients with EGFR -mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial

(2017) Yi-Long Wu et al.   LANCET ONCOLOGY

A highly efficient and sensitive LC-MS/MS method for the determination of afatinib in human plasma: application to a metabolic stability study

(2016) Adnan A. Kadi et al.   BIOMEDICAL CHROMATOGRAPHY

Osimertinib Western and Asian clinical pharmacokinetics in patients and healthy volunteers: implications for formulation, dose, and dosing frequency in pivotal clinical studies

(2016) David Planchard et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Pharmacokinetic parameters of gefitinib predict efficacy and toxicity in patients with advanced non-small cell lung cancer harboring EGFR mutations

(2016) Kosuke Mizoguchi et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Clinical Pharmacokinetics and Pharmacodynamics of Afatinib

(2016) Sven Wind et al.   CLINICAL PHARMACOKINETICS

Simultaneous and rapid determination of gefitinib, erlotinib and afatinib plasma levels using liquid chromatography/tandem mass spectrometry in patients with non-small-cell lung cancer

(2015) Hideki Hayashi et al.   BIOMEDICAL CHROMATOGRAPHY

Practical Guidelines for Therapeutic Drug Monitoring of Anticancer Tyrosine Kinase Inhibitors: Focus on the Pharmacokinetic Targets

(2014) Huixin Yu et al.   CLINICAL PHARMACOKINETICS

AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer

(2014) D. A. E. Cross et al.   Cancer Discovery

A phase I, open-label, mass balance study of [14C] dacomitinib (PF-00299804) in healthy male volunteers

(2013) Carlo L. Bello et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Phase I and pharmacokinetic study of dacomitinib (PF-00299804), an oral irreversible, small molecule inhibitor of human epidermal growth factor receptor-1, -2, and -4 tyrosine kinases, in Japanese patients with advanced solid tumors

(2012) Toshiaki Takahashi et al.   INVESTIGATIONAL NEW DRUGS